Magnetic Resonance Imaging, Iron Oxide Nanoparticles, and Targeted Drug Delivery
This community develops magnetic nanoparticles and contrast agents for MRI diagnostics and targeted drug delivery, with a specific focus on overcoming the blood-brain barrier for neurological and oncological treatments.
The research centers on the synthesis and application of superparamagnetic iron oxide nanoparticles (SPIONs) and gadolinium-based agents. These materials serve dual purposes: enhancing image contrast in magnetic resonance imaging and acting as carriers for therapeutic payloads. Key applications include targeted delivery of gene therapies, siRNA, and small molecules to tumors and the brain. The work frequently involves engineering nanoparticles to cross the blood-brain barrier, treating conditions such as glioblastoma, Alzheimer’s disease, and Pompe disease. Recurring methods include dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the use of extracellular vesicles or exosomes as delivery vehicles.
The largest share of the community's output is found in gadolinium research, accounting for 20.8% of all gadolinium research, and 13,059 papers here. This is the element with the highest paper count within this group.
The community comprises 82,547 papers, published primarily in the Journal of Magnetic Resonance Imaging, Magnetic Resonance Imaging, and Magnetic Resonance in Medicine.
Recent work focuses on engineered exosomes for targeted gene therapy in pancreatic cancer, modulation of blood-brain barrier transport for amyloid clearance, and the development of novel nanoformulations for brain-targeted delivery of drugs like quercetin and agomelatine.